-+ 0.00%
-+ 0.00%
-+ 0.00%

Dogwood Therapeutics licenses IMC-1, IMC-2 antivirals to PRIDCor in deal up to $100 million

PUBT·04/23/2026 13:00:48
Listen to the news
Dogwood Therapeutics licenses IMC-1, IMC-2 antivirals to PRIDCor in deal up to $100 million
  • Dogwood Therapeutics entered a global development and commercialization partnership with PRIDCor Therapeutics for antiviral candidates IMC-1 and IMC-2.
  • PRIDCor received worldwide rights for all indications, including fibromyalgia and Long-COVID.
  • PRIDCor will fund future development, commercialization, and intellectual property maintenance for both assets.
  • Dogwood will receive tiered royalties up to 15% on net sales if IMC-1 or IMC-2 are commercialized.
  • Agreement includes potential payments capped at USD 100 million, including 9% of future PRIDCor capital raised to advance IMC-1 or IMC-2.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief on April 23, 2026, and is solely responsible for the information contained therein.